Hims & Hers Health (HIMS) has restarted its collaboration with Novo Nordisk, bringing FDA-approved GLP-1 drugs like Wegovy and Ozempic back to its platform alongside a new subscription based weight loss membership program.
See our latest analysis for Hims & Hers Health.
The latest 1 day share price return of 6.22% to US$20.33 extends a 7 day gain of 8.25% and a 1 month share price return of 29.16%. This follows a 90 day share price decline of 42.67% and a 1 year total shareholder return of 26.79% in the red, set against a very large 3 year total shareholder return that is more than double.
If renewed interest in GLP-1 exposure has your attention, this can be a good moment to see what else is moving in telehealth and weight loss related names through 37 healthcare AI stocks
With the share price still below analyst targets and an implied intrinsic value gap, the renewed Novo Nordisk tie up and GLP 1 offering raises a simple question for you: is there still upside here, or has the market already priced in future growth?
Most Popular Narrative: 76% Undervalued
According to the most followed narrative on Simply Wall St, Hims & Hers Health's fair value of $86.09 sits well above the last close at $20.33. This frames the renewed GLP-1 tie up as only part of a much bigger story.
Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock. It is quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco by delivering more value per dollar spent, reinvesting scale advantages, and aiming to win via customer-centric efficiency.
Curious how that $86.09 figure is reached? The narrative leans on rapid revenue expansion, rising profitability, and a premium earnings multiple that assumes meaningful operating scale yet to be reflected in the current share price.
Result: Fair Value of $86.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, risks around tighter GLP 1 regulation and future partnerships with large drug makers could challenge the idea that Hims & Hers is simply mispriced.
Find out about the key risks to this Hims & Hers Health narrative.
Next Steps
With mixed signals around risk and reward in this story, it can be useful to move quickly and test the thesis against hard data for yourself using 3 key rewards and 3 important warning signs
Ready to hunt for more investment ideas?
If this GLP 1 story has sparked your interest, do not stop here. Use targeted stock lists to uncover other opportunities that fit your style.
- Target resilient compounding potential by scanning companies in the 62 high quality undervalued stocks and see which names the market may be overlooking right now.
- Lock in potential income streams by reviewing the 13 dividend fortresses and spot businesses that pair higher yields with staying power.
- Prioritise resilience first by checking the 68 resilient stocks with low risk scores and focus on companies with steadier profiles when markets turn choppy.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com